NTX-1472
Phase 2Small molecule
NTX-1472 is one of 44 small molecule programs targeting Social Anxiety Disorder. It is currently in Phase 2.
2
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
47 competitors in Social Anxiety Disorder
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Lexapro
AbbVieApproved
Vraylar
AbbVieApproved
Zoloft
VViatris Specialty LLC
Approved
Paxil
SSebela Pharmaceuticals Development LLC
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Effexor
WWyeth-Lederle Vaccines
Approved
Klonopin
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Transderm Scop
BBaxter Healthcare Corporation
Approved
Botulinum Toxin a
GSKApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NTX-1472. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNewleos Therapeutics, Inc.